

• Provide direct observation therapy during residency until the patient demonstrates the knowledge and ability to self administer doses appropriately.

The purpose of this grant is to demonstrate how compliance with the complicated medication regimen for people living with HIV and AIDS who are at high risk of noncompliance can be increased by a short-term residential treatment program. The START program provides these individuals with a sheltered, structured environment in which the regimen can be established and residents can be counseled and supported.

This award is made based on the authority granted by section 1110 of the Social Security Act (the Act). Section 1110 of the Act authorizes appropriations each fiscal year for grants to pay for part of the cost of research or demonstration projects that will improve the administration and effectiveness of programs. The demonstration project above has been reviewed by our specialists and has been deemed to meet these qualifications.

(Catalog of Federal Domestic Assistance Program No. 93.778, Medical Assistance Program; No. 93.773 Medicare—Hospital Insurance Program; and No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: February 26, 1999.

Nancy-Ann Min DeParle,

Administrator, Health Care Financing Administration.

[FR Doc. 99-5325 Filed 3-3-99; 8:45 am]

BILLING CODE 4120-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies, and Laboratories That Have Withdrawn From the Program

AGENCY: Substance Abuse and Mental Health Services Administration, HHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services notifies Federal agencies of the laboratories currently certified to meet standards of Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs (59 FR 29916, 29925). A similar notice listing all currently certified laboratories will be published during the first week of each month, and updated to include laboratories which subsequently apply

for and complete the certification process. If any listed laboratory's certification is totally suspended or revoked, the laboratory will be omitted from updated lists until such time as it is restored to full certification under the Guidelines.

If any laboratory has withdrawn from the National Laboratory Certification Program during the past month, it will be identified as such at the end of the current list of certified laboratories, and will be omitted from the monthly listing thereafter.

This Notice is now available on the internet at the following website: <http://www.health.org/workpl.htm>

FOR FURTHER INFORMATION CONTACT: Mrs. Giselle Hersh or Dr. Walter Vogl, Division of Workplace Programs, 5600 Fishers Lane, Rockwall 2 Building, Room 815, Rockville, Maryland 20857; Tel.: (301) 443-6014.

Special Note: Our office moved to a different building on May 18, 1998. Please use the above address for all regular mail and correspondence. For all overnight mail service use the following address: Division of Workplace Programs, 5515 Security Lane, Room 815, Rockville, Maryland 20852.

SUPPLEMENTARY INFORMATION: Mandatory Guidelines for Federal Workplace Drug Testing were developed in accordance with Executive Order 12564 and section 503 of Pub. L. 100-71. Subpart C of the Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards which laboratories must meet in order to conduct urine drug testing for Federal agencies. To become certified an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that certification a laboratory must participate in a quarterly performance testing program plus periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements expressed in the HHS Guidelines. A laboratory must have its letter of certification from SAMHSA, HHS (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Guidelines, the following laboratories meet the minimum standards set forth in the Guidelines:

ACL Laboratories, 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-7840, (formerly: Bayshore Clinical Laboratory)
Advanced Toxicology Network, 15201 East I-10 Freeway, Suite 125,

Channelview, TX 77530, 713-457-3784/800-888-4063, (formerly: Drug Labs of Texas, Premier Analytical Laboratories)

Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615-255-2400

Alabama Reference Laboratories, Inc., 543 South Hull St., Montgomery, AL 36103, 800-541-4931/334-263-5745

Alliance Laboratory Services, 3200 Burnet Ave., Cincinnati, OH 45229, 513-585-9000, (formerly: Jewish Hospital of Cincinnati, Inc.)

American Medical Laboratories, Inc., 14225 Newbrook Dr., Chantilly, VA 20151, 703-802-6900

Associated Pathologists Laboratories, Inc., 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866 / 800-433-2750

Associated Regional and University Pathologists, Inc. (ARUP), 500 Chipeta Way, Salt Lake City, UT 84108, 801-583-2787 / 800-242-2787

Baptist Medical Center—Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-202-2783, (formerly: Forensic Toxicology Laboratory Baptist Medical Center) Clinical Reference Lab, 8433 Quivira Rd., Lenexa, KS 66215-2802, 800-445-6917

Cox Health Systems, Department of Toxicology, 1423 North Jefferson Ave., Springfield, MO 65802, 800-876-3652/417-269-3093, (formerly: Cox Medical Centers)

Dept. of the Navy, Navy Drug Screening Laboratory, Great Lakes, IL, P. O. Box 88-6819, Great Lakes, IL 60088-6819, 847-688-2045/847-688-4171

Diagnostic Services Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 941-561-8200/800-735-5416

Doctors Laboratory, Inc., P.O. Box 2658, 2906 Julia Dr., Valdosta, GA 31604, 912-244-4468

DrugProof, Division of Dynacare/Laboratory of Pathology, LLC, 1229 Madison St., Suite 500, Nordstrom Medical Tower, Seattle, WA 98104 800-898-0180/206-386-2672, (formerly: Laboratory of Pathology of Seattle, Inc., DrugProof, Division of Laboratory of Pathology of Seattle, Inc.)

DrugScan, Inc., P.O. Box 2969, 1119 Mearns Rd, Warminster, PA 18974, 215-674-9310

Dynacare Kasper Medical Laboratories,* 14940-123 Ave., Edmonton, Alberta, Canada T5V 1B4, 800-661-9876/403-451-3702

ElSohly Laboratories, Inc., 5 Industrial Park Dr., Oxford, MS 38655, 601-236-2609

Gamma-Dynacare Medical Laboratories,* 1A Division of the

- Gamma-Dynacare Laboratory Partnership, 245 Pall Mall St., London, ON, Canada N6A 1P4, 519-679-1630
- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6267
- Hartford Hospital Toxicology Laboratory, 80 Seymour St., Hartford, CT 06102-5037, 860-545-6023
- Info-Meth, 112 Crescent Ave., Peoria, IL 61636, 800-752-1835/309-671-5199 (Formerly: Methodist Medical Center Toxicology Laboratory)
- Integrated Regional Laboratories, 1400 Northwest 12th Ave., Miami, FL 33136, 305-325-5784 (Formerly: Cedars Medical Center, Department of Pathology)
- LabCorp Occupational Testing Services, Inc., 1904 Alexander Drive, Research Triangle Park, NC 27709, 919-672-6900/800-833-3984 (Formerly: CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group)
- LabCorp Occupational Testing Services, Inc., 4022 Willow Lake Blvd., Memphis, TN 38118, 901-795-1515/800-223-6339 (Formerly: MedExpress/National Laboratory Center)
- LabOne, Inc., 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927 / 800-728-4064 (formerly: Center for Laboratory Services, a Division of LabOne, Inc.)
- Laboratory Corporation of America, 888 Willow St., Reno, NV 89502, 702-334-3400 (formerly: Sierra Nevada Laboratories, Inc.)
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 800-437-4986/908-526-2400 (Formerly: Roche Biomedical Laboratories, Inc.)
- Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504-361-8989/800-433-3823
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715-389-3734/800-331-3734
- MAXXAM Analytics Inc.,* 5540 McAdam Rd., Mississauga, ON, Canada L4Z 1P1, 905-890-2555 (formerly: NOVAMANN (Ontario) Inc.)
- Medical College Hospitals Toxicology Laboratory, Department of Pathology, 3000 Arlington Ave., Toledo, OH 43614, 419-383-5213
- MedTox Laboratories, Inc., 402 W. County Rd. D, St. Paul, MN 55112, 800-832-3244/651-636-7466
- Methodist Hospital Toxicology Services of Clarian Health Partners, Inc., Department of Pathology and Laboratory Medicine, 1701 N. Senate Blvd., Indianapolis, IN 46202, 317-929-3587
- MetroLab-Legacy Laboratory Services, 1225 NE., 2nd Ave., Portland, OR 97232, 503-413-4512, 800-950-5295
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, Minnesota 55417, 612-725-2088
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 805-322-4250
- NWT Drug Testing, 1141 E. 3900 South, Salt Lake City, UT 84124, 800-322-3361/801-268-2431 (Formerly: NorthWest Toxicology, Inc.)
- Oregon Medical Laboratories, P.O. Box 972, 722 East 11th Ave., Eugene, OR 97440-0972, 541-341-8092
- Pacific Toxicology Laboratories, 6160 Variel Ave., Woodland Hills, CA 91367, 818-598-3110 (Formerly: Centinela Hospital Airport Toxicology Laboratory)
- Pathology Associates Medical Laboratories, 11604 E. Indiana, Spokane, WA 99206, 509-926-2400/800-541-7891
- PharmChem Laboratories, Inc., 1505-A O'Brien Dr., Menlo Park, CA 94025, 650-328-6200/800-446-5177
- PharmChem Laboratories, Inc., Texas Division, 7610 Pebble Dr., Fort Worth, TX 76118, 817-595-0294 (Formerly: Harris Medical Laboratory)
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913-339-0372/800-821-3627
- Poisonlab, Inc., 7272 Clairemont Mesa Blvd., San Diego, CA 92111, 619-279-2600/800-882-7272
- Quest Diagnostics Incorporated, 4444 Giddings Road, Auburn Hills, MI 48326, 810-373-9120/800-444-0106 (Formerly: HealthCare/Preferred Laboratories, HealthCare/MetPath, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, National Center for Forensic Science, 1901 Sulphur Spring Rd., Baltimore, MD 21227, 410-536-1485 (Formerly: Maryland Medical Laboratory, Inc., National Center for Forensic Science, CORNING National Center for Forensic Science)
- Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 800-526-0947/972-916-3376 (Formerly: Damon Clinical Laboratories, Damon/MetPath, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, 875 Greentree Rd., 4 Parkway Ctr., Pittsburgh, PA 15220-3610, 800-574-2474/412-920-7733 (Formerly: Med-Chek Laboratories, Inc., Med-Chek/Damon, MetPath Laboratories, CORNING Clinical Laboratories)
- Quest Diagnostics of Missouri LLC, 2320 Schuetz Rd., St. Louis, MO 63146, 800-288-7293/314-991-1311 (Formerly: Quest Diagnostics Incorporated, Metropolitan Reference Laboratories, Inc., CORNING Clinical Laboratories, South Central Division)
- Quest Diagnostics Incorporated, 7470 Mission Valley Rd., San Diego, CA 92108-4406, 800-446-4728/619-686-3200 (Formerly: Nichols Institute, Nichols Institute Substance Abuse Testing (NISAT), CORNING Nichols Institute, CORNING Clinical Laboratories)
- Quest Diagnostics Incorporated, One Malcolm Ave., Teterboro, NJ 07608, 201-393-5590 (Formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories, CORNING Clinical Laboratory)
- Quest Diagnostics Incorporated, 1355 Mittel Blvd., Wood Dale, IL 60191, 630-595-3888 (Formerly: MetPath, Inc., CORNING MetPath Clinical Laboratories, CORNING Clinical Laboratories Inc.)
- Scientific Testing Laboratories, Inc., 463 Southlake Blvd., Richmond, VA 23236, 804-378-9130
- Scott & White Drug Testing Laboratory, 600 S. 31st St., Temple, TX 76504, 800-749-3788/254-771-8379
- S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505-727-6300/800-999-5227
- SmithKline Beecham Clinical Laboratories, 3175 Presidential Dr., Atlanta, GA 30340, 770-452-1590, (Formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 8000 Sovereign Row, Dallas, TX 75247, 214-637-7236 (Formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 801 East Dixie Ave., Leesburg, FL 34748, 352-787-9006 (Formerly: Doctors & Physicians Laboratory)
- SmithKline Beecham Clinical Laboratories, 400 Egypt Rd., Norristown, PA 19403, 800-877-7484/610-631-4600 (Formerly: SmithKline Bio-Science Laboratories)
- SmithKline Beecham Clinical Laboratories, 506 E. State Pkwy., Schaumburg, IL 60173, 847-447-4379/800-447-4379 (Formerly: International Toxicology Laboratories)
- SmithKline Beecham Clinical Laboratories, 7600 Tyrone Ave., Van Nuys, CA 91405, 818-989-2520/800-877-2520

South Bend Medical Foundation, Inc.,
530 N. Lafayette Blvd., South Bend,
IN 46601, 219-234-4176

Southwest Laboratories, 2727 W.
Baseline Rd., Tempe, AZ 85283, 602-
438-8507

Sparrow Health System, Toxicology
Testing Center, St. Lawrence Campus,
1210 W. Saginaw, Lansing, MI 48915,
517-377-0520 (Formerly: St.
Lawrence Hospital & Healthcare
System)

St. Anthony Hospital Toxicology
Laboratory, 1000 N. Lee St.,
Oklahoma City, OK 73101, 405-272-
7052

Toxicology & Drug Monitoring
Laboratory, University of Missouri
Hospital & Clinics, 2703 Clark Lane,
Suite B, Lower Level, Columbia, MO
65202, 573-882-1273

Toxicology Testing Service, Inc., 5426
NW. 79th Ave., Miami, FL 33166,
305-593-2260

UNILAB, 18408 Oxnard St., Tarzana,
CA 91356, 800-492-0800/818-996-
7300 (Formerly: MetWest-BPL
Toxicology Laboratory)

Universal Toxicology Laboratories, LLC,
10210 W. Highway 80, Midland,
Texas 79706, 915-561-8851/888-
953-8851

UTMB Pathology-Toxicology
Laboratory, University of Texas
Medical Branch, Clinical Chemistry

Division, 301 University Boulevard,
Room 5.158, Old John Sealy,
Galveston, Texas 77555-0551, 409-
772-3197

* The Standards Council of Canada (SCC)
voted to end its Laboratory Accreditation
Program for Substance Abuse (LAPSA)
effective May 12, 1998. Laboratories certified
through that program were accredited to
conduct forensic urine drug testing as
required by U.S. Department of
Transportation (DOT) regulations. As of that
date, the certification of those accredited
Canadian laboratories will continue under
DOT authority. The responsibility for
conducting quarterly performance testing
plus periodic on-site inspections of those
LAPSA-accredited laboratories was
transferred to the U.S. DHHS, with the
DHHS' National Laboratory Certification
Program (NLCP) contractor continuing to
have an active role in the performance testing
and laboratory inspection processes. Other
Canadian laboratories wishing to be
considered for the NLCP may apply directly
to the NLCP contractor just as U.S.
laboratories do. Upon finding a Canadian
laboratory to be qualified, the DHHS will
recommend that DOT certify the laboratory
(Federal Register, 16 July 1996) as meeting
the minimum standards of the "Mandatory
Guidelines for Workplace Drug Testing" (59
Federal Register, 9 June 1994, Pages 29908-
29931). After receiving the DOT certification,
the laboratory will be included in the
monthly list of DHHS certified laboratories

and participate in the NLCP certification
maintenance program.

Richard Kopanda,
*Executive Officer, Substance Abuse and
Mental Health Services Administration.*
[FR Doc. 99-5424 Filed 3-3-99; 8:45 am]
BILLING CODE 4160-20-U

**DEPARTMENT OF HEALTH AND
HUMAN SERVICES**

**Substance Abuse and Mental Health
Services Administration**

**Fiscal Year (FY) 1999 Funding
Opportunities**

AGENCY: Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice of funding availability.

SUMMARY: The Substance Abuse and
Mental Health Services Administration
(SAMHSA) Center for Substance Abuse
Treatment (CSAT), announces the
availability of FY 1999 funds for grants
for the following activity. This activity
is discussed in more detail under
Section 4 of this notice. This notice is
not a complete description of the
activity; potential applicants *must*
obtain a copy of the Guidance for
Applicants (GFA) before preparing an
application.

Activity	Application dead- line	Estimated funds available	Estimated number of awards	Project period
Adolescent Treatment Models	5/10/99	\$4 Million	12	Up to 3 yrs.

Note: SAMHSA will publish additional
notices of available funding opportunities for
FY 1999 in subsequent issues of the **Federal
Register**.

The actual amount available for
awards and their allocation may vary,
depending on unanticipated program
requirements and the number and
quality of applications received. FY
1999 funds for the activity discussed in
this announcement were appropriated
by the Congress under Public Law No.
105-277. SAMHSA's policies and
procedures for peer review and
Advisory Council review of grant and
cooperative agreement applications
were published in the **Federal Register**
(Vol. 58, No. 126) on July 2, 1993.

The Public Health Service (PHS) is
committed to achieving the health
promotion and disease prevention
objectives of Healthy People 2000, a
PHS-led national activity for setting
priority areas. The SAMHSA Centers'
substance abuse and mental health
services activities address issues related

to Healthy People 2000 objectives of
Mental Health and Mental Disorders;
Alcohol and Other Drugs; Clinical
Preventive Services; HIV Infection; and
Surveillance and Data Systems.
Potential applicants may obtain a copy
of Healthy People 2000 (Full Report:
Stock No. 017-001-00474-0) or
Summary Report: Stock No. 017-001-
00473-1) through the Superintendent of
Documents, Government Printing
Office, Washington, DC 20402-9325
(Telephone: 202-512-1800).

General Instructions: Applicants must
use application form PHS 5161-1 (Rev.
5/96; OMB No. 0937-0189). The
application kit contains the GFA
(complete programmatic guidance and
instructions for preparing and
submitting applications), the PHS 5161-
1 which includes Standard Form 424
(Face Page), and other documentation
and forms. Application kits may be
obtained from the organization specified
for the activity covered by this notice
(see Section 4).

When requesting an application kit,
the applicant must specify the particular
activity for which detailed information
is desired. This is to ensure receipt of
all necessary forms and information,
including any specific program review
and award criteria.

The PHS 5161-1 application form and
the full text of the activity (i.e., the GFA)
described in Section 4 are available
electronically via SAMHSA's World
Wide Web Home Page (address: [http://
www.samhsa.gov](http://www.samhsa.gov)).

Application Submission: Applications
must be submitted to:
SAMHSA Programs, Center for
Scientific Review, National Institutes
of Health, Suite 1040, 6701 Rockledge
Drive MSC-7710, Bethesda, Maryland
20892-7710.*

* Applicants who wish to use express mail
or courier service should change the zip code
to 20817.

Application Deadlines: The deadline
for receipt of applications is listed in the
table above.